Titan Pharmaceuticals Inc.

BioMarin Pharmaceutical Inc. followed up its recent announcement of a shift in research and development priorities and a new commercial strategy for its hemophilia A gene therapy Roctavian (valoctoco

Executive changes in the off-patent medicines industry throughout 2023 reflected a growing interest in the innovator side of the life sciences sector among leading generics and biosimilars companies.

In 2023, Viatris Inc. continued its efforts to pivot from off-patent products toward innovative operations, offloading four of its businesses including its six-facility-strong active pharmaceutical

Infectious disease provided the backdrop for both of the US FDA’s novel approvals last week, one an antiviral and one an antibiotic. The antiviral is already familiar to patients and prescribers. Pfi